PLGA, PLA, PCL polymers for Controlled Drug Delivery

Introduction Burst release in PLGA formulations is one of the most clinically consequential — and analytically challenging — phenomena in […]

Introduction: Carmustine PLGA characterization sits at the intersection of polymer science, oncology pharmacology, and regulatory compliance — making it one

Introduction: Aripiprazole lauroxil (Aristada®) is a PLGA-based long-acting injectable antipsychotic that differs fundamentally from other LAI microsphere products. As discussed

Introduction: Goserelin PLGA implant characterization is one of the most technically demanding challenges in long-acting parenteral development — and also

Introduction to Interfacial Dynamics of Surfactants and Emulsifiers in PLGA Microsphere Fabrication The primary function of surfactants and emulsifiers in

Introduction: Naltrexone PLGA microsphere burst release is one of the most technically demanding problems in long-acting injectable (LAI) formulation science.

Introduction Sustained-release ocular drug delivery continues to represent a major bioengineering challenge because the eye possesses multiple anatomical and physiological

Introduction: Why the Erosion Mechanism Is Everything The most critical factor in PLGA formulation design is not particle size or

Introduction: Why Characterization of Long-Acting Biologics in PLGA Demands a Dedicated Framework The characterization of long-acting biologics encapsulated within poly(lactic-co-glycolic